Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 47 | 2024 | 682 | 9.440 |
Why?
|
| Veterans | 47 | 2024 | 728 | 8.800 |
Why?
|
| Mental Disorders | 35 | 2024 | 717 | 8.120 |
Why?
|
| Criminals | 10 | 2024 | 53 | 4.360 |
Why?
|
| Recidivism | 7 | 2024 | 26 | 3.720 |
Why?
|
| Cocaine-Related Disorders | 19 | 2017 | 82 | 3.370 |
Why?
|
| Opioid-Related Disorders | 20 | 2024 | 456 | 2.850 |
Why?
|
| Mental Health Services | 16 | 2022 | 268 | 2.650 |
Why?
|
| Residential Treatment | 6 | 2022 | 30 | 2.120 |
Why?
|
| Social Stigma | 4 | 2017 | 64 | 2.070 |
Why?
|
| Housing | 9 | 2024 | 72 | 1.970 |
Why?
|
| United States Department of Veterans Affairs | 27 | 2024 | 519 | 1.910 |
Why?
|
| Mental Health | 13 | 2023 | 335 | 1.740 |
Why?
|
| Criminal Law | 7 | 2021 | 70 | 1.720 |
Why?
|
| Schizophrenia | 13 | 2009 | 242 | 1.670 |
Why?
|
| Cocaine | 15 | 2017 | 96 | 1.590 |
Why?
|
| Behavior, Addictive | 6 | 2016 | 72 | 1.560 |
Why?
|
| Humans | 122 | 2024 | 59360 | 1.490 |
Why?
|
| Adult | 65 | 2024 | 15669 | 1.450 |
Why?
|
| Antipsychotic Agents | 11 | 2009 | 292 | 1.340 |
Why?
|
| United States | 39 | 2024 | 7390 | 1.340 |
Why?
|
| Coercion | 2 | 2022 | 58 | 1.330 |
Why?
|
| Substance Withdrawal Syndrome | 13 | 2005 | 119 | 1.310 |
Why?
|
| Pilot Projects | 15 | 2024 | 914 | 1.300 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 11 | 2024 | 79 | 1.220 |
Why?
|
| Male | 64 | 2024 | 27739 | 1.180 |
Why?
|
| Community Mental Health Services | 3 | 2019 | 88 | 1.170 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 79 | 1.170 |
Why?
|
| Peer Group | 6 | 2020 | 95 | 1.100 |
Why?
|
| Program Evaluation | 3 | 2019 | 470 | 1.060 |
Why?
|
| Morals | 5 | 2022 | 21 | 1.060 |
Why?
|
| Female | 56 | 2024 | 30705 | 0.980 |
Why?
|
| Mentoring | 2 | 2022 | 46 | 0.970 |
Why?
|
| Risperidone | 6 | 2006 | 24 | 0.930 |
Why?
|
| Analgesics, Opioid | 7 | 2024 | 483 | 0.930 |
Why?
|
| Middle Aged | 44 | 2024 | 16317 | 0.920 |
Why?
|
| Cues | 9 | 2017 | 73 | 0.860 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 380 | 0.820 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 408 | 0.800 |
Why?
|
| Case Management | 3 | 2020 | 54 | 0.770 |
Why?
|
| Benzodiazepines | 4 | 2018 | 94 | 0.730 |
Why?
|
| Prisons | 3 | 2019 | 105 | 0.700 |
Why?
|
| Drug Overdose | 2 | 2021 | 126 | 0.680 |
Why?
|
| Schizophrenic Psychology | 5 | 2009 | 65 | 0.680 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 117 | 0.670 |
Why?
|
| Opiate Substitution Treatment | 7 | 2024 | 187 | 0.670 |
Why?
|
| Social Support | 2 | 2019 | 355 | 0.660 |
Why?
|
| Electroretinography | 9 | 2001 | 26 | 0.650 |
Why?
|
| Tobacco Use Disorder | 6 | 2023 | 243 | 0.650 |
Why?
|
| Social Perception | 1 | 2019 | 38 | 0.640 |
Why?
|
| Psychiatry | 1 | 2021 | 114 | 0.640 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2019 | 14 | 0.630 |
Why?
|
| Pharmacies | 1 | 2018 | 34 | 0.610 |
Why?
|
| Task Performance and Analysis | 2 | 2018 | 122 | 0.610 |
Why?
|
| Comorbidity | 9 | 2018 | 1078 | 0.600 |
Why?
|
| Educational Technology | 1 | 2018 | 9 | 0.590 |
Why?
|
| Craving | 5 | 2024 | 35 | 0.580 |
Why?
|
| Recovery of Function | 1 | 2019 | 270 | 0.570 |
Why?
|
| Crime | 1 | 2018 | 50 | 0.560 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 77 | 0.560 |
Why?
|
| Attitude to Health | 1 | 2019 | 279 | 0.550 |
Why?
|
| Massachusetts | 8 | 2022 | 2002 | 0.540 |
Why?
|
| Cell Phone | 2 | 2014 | 42 | 0.530 |
Why?
|
| Buprenorphine | 5 | 2023 | 181 | 0.530 |
Why?
|
| Informed Consent | 1 | 2017 | 138 | 0.520 |
Why?
|
| Learning | 1 | 2018 | 169 | 0.520 |
Why?
|
| Research | 1 | 2016 | 188 | 0.480 |
Why?
|
| Treatment Outcome | 12 | 2019 | 5284 | 0.480 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 175 | 0.460 |
Why?
|
| Smoking Cessation | 5 | 2023 | 541 | 0.450 |
Why?
|
| Algorithms | 3 | 2020 | 976 | 0.440 |
Why?
|
| Cognition Disorders | 3 | 2015 | 215 | 0.430 |
Why?
|
| Internet | 2 | 2014 | 448 | 0.420 |
Why?
|
| Neuropsychological Tests | 6 | 2003 | 371 | 0.410 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 14 | 0.400 |
Why?
|
| Breathing Exercises | 1 | 2012 | 5 | 0.400 |
Why?
|
| Receptors, GABA-A | 1 | 2012 | 23 | 0.400 |
Why?
|
| Primary Health Care | 2 | 2017 | 643 | 0.400 |
Why?
|
| Counseling | 5 | 2023 | 349 | 0.390 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 147 | 0.370 |
Why?
|
| Prisoners | 3 | 2019 | 151 | 0.360 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2009 | 379 | 0.360 |
Why?
|
| Psychotherapy, Brief | 1 | 2010 | 16 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 439 | 0.340 |
Why?
|
| Telemedicine | 2 | 2014 | 307 | 0.340 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 521 | 0.330 |
Why?
|
| Alcoholism | 5 | 2021 | 309 | 0.330 |
Why?
|
| Cluster Analysis | 3 | 2019 | 245 | 0.300 |
Why?
|
| Neural Pathways | 1 | 2008 | 95 | 0.300 |
Why?
|
| Young Adult | 9 | 2024 | 4267 | 0.290 |
Why?
|
| Stress, Psychological | 2 | 2024 | 442 | 0.290 |
Why?
|
| Depression | 2 | 2012 | 828 | 0.280 |
Why?
|
| Telephone | 3 | 2023 | 115 | 0.270 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 159 | 0.270 |
Why?
|
| Stereotyping | 2 | 2016 | 17 | 0.270 |
Why?
|
| Social Discrimination | 2 | 2016 | 12 | 0.270 |
Why?
|
| Feasibility Studies | 3 | 2021 | 525 | 0.270 |
Why?
|
| Veterans Health | 5 | 2021 | 158 | 0.270 |
Why?
|
| Psychotherapy | 2 | 2017 | 92 | 0.270 |
Why?
|
| Prejudice | 2 | 2016 | 60 | 0.260 |
Why?
|
| Monitoring, Ambulatory | 3 | 2015 | 56 | 0.260 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 84 | 0.250 |
Why?
|
| Substance Abuse Detection | 2 | 2015 | 44 | 0.240 |
Why?
|
| Qualitative Research | 5 | 2021 | 618 | 0.240 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 15 | 0.230 |
Why?
|
| Serotonin Antagonists | 1 | 2004 | 30 | 0.230 |
Why?
|
| Behavior Therapy | 2 | 2024 | 161 | 0.220 |
Why?
|
| Health Status | 3 | 2020 | 424 | 0.220 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2373 | 0.220 |
Why?
|
| Smoking Prevention | 2 | 2015 | 158 | 0.210 |
Why?
|
| Wearable Electronic Devices | 2 | 2024 | 62 | 0.210 |
Why?
|
| Retinal Cone Photoreceptor Cells | 4 | 1997 | 25 | 0.210 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2002 | 8 | 0.210 |
Why?
|
| World Health Organization | 1 | 2022 | 30 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 450 | 0.200 |
Why?
|
| Epidemics | 1 | 2022 | 22 | 0.190 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2017 | 23 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2337 | 0.190 |
Why?
|
| Cannabidiol | 1 | 2020 | 6 | 0.180 |
Why?
|
| Health Planning | 1 | 2021 | 29 | 0.180 |
Why?
|
| Social Problems | 1 | 2020 | 4 | 0.180 |
Why?
|
| Outpatients | 2 | 2012 | 136 | 0.180 |
Why?
|
| Interview, Psychological | 2 | 2017 | 73 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1479 | 0.170 |
Why?
|
| Public Housing | 1 | 2020 | 12 | 0.170 |
Why?
|
| Employment | 1 | 2021 | 123 | 0.170 |
Why?
|
| Patient Compliance | 3 | 2013 | 349 | 0.170 |
Why?
|
| Aged | 12 | 2021 | 13416 | 0.170 |
Why?
|
| Vaping | 1 | 2020 | 44 | 0.170 |
Why?
|
| Sex Factors | 3 | 2018 | 935 | 0.160 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 71 | 0.160 |
Why?
|
| Public Opinion | 1 | 2019 | 22 | 0.160 |
Why?
|
| Health Plan Implementation | 2 | 2017 | 40 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 741 | 0.160 |
Why?
|
| Gambling | 2 | 2016 | 18 | 0.160 |
Why?
|
| Diabetes Mellitus | 3 | 2009 | 515 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 677 | 0.160 |
Why?
|
| Methadone | 4 | 2023 | 127 | 0.160 |
Why?
|
| Double-Blind Method | 5 | 2015 | 715 | 0.150 |
Why?
|
| Community Health Centers | 1 | 2019 | 89 | 0.150 |
Why?
|
| Tobacco Use | 1 | 2018 | 37 | 0.150 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 1998 | 21 | 0.150 |
Why?
|
| Recurrence | 4 | 2015 | 603 | 0.150 |
Why?
|
| Boston | 1 | 2019 | 246 | 0.150 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 203 | 0.140 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 288 | 0.140 |
Why?
|
| Color Vision Defects | 1 | 1997 | 1 | 0.140 |
Why?
|
| Program Development | 1 | 2019 | 203 | 0.140 |
Why?
|
| Psychology, Clinical | 1 | 1997 | 7 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 167 | 0.140 |
Why?
|
| Needs Assessment | 2 | 2024 | 187 | 0.140 |
Why?
|
| Los Angeles | 1 | 2017 | 11 | 0.140 |
Why?
|
| Dopamine | 3 | 2008 | 102 | 0.140 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 442 | 0.140 |
Why?
|
| Legislation, Medical | 1 | 2017 | 4 | 0.140 |
Why?
|
| Thinking | 1 | 2017 | 28 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2018 | 215 | 0.140 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 550 | 0.140 |
Why?
|
| Pandemics | 1 | 2022 | 615 | 0.140 |
Why?
|
| Logistic Models | 3 | 2020 | 1232 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2018 | 135 | 0.140 |
Why?
|
| Risk Factors | 3 | 2019 | 4984 | 0.130 |
Why?
|
| Culture | 1 | 2017 | 73 | 0.130 |
Why?
|
| Adolescent | 7 | 2021 | 5824 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 186 | 0.130 |
Why?
|
| Social Justice | 1 | 2016 | 29 | 0.120 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2015 | 25 | 0.120 |
Why?
|
| Memantine | 1 | 2015 | 22 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 332 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1504 | 0.120 |
Why?
|
| Haloperidol | 2 | 2006 | 15 | 0.120 |
Why?
|
| Naloxone | 1 | 2015 | 57 | 0.120 |
Why?
|
| Risk-Taking | 1 | 2016 | 158 | 0.120 |
Why?
|
| Depressive Disorder | 1 | 2017 | 279 | 0.120 |
Why?
|
| Bipolar Disorder | 2 | 2009 | 243 | 0.110 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 121 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 55 | 0.110 |
Why?
|
| Hospitalization | 2 | 2018 | 1290 | 0.110 |
Why?
|
| Reminder Systems | 1 | 2014 | 72 | 0.110 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 113 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2013 | 2513 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2022 | 3067 | 0.100 |
Why?
|
| Cognition | 3 | 2023 | 455 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 451 | 0.100 |
Why?
|
| Clinical Competence | 1 | 1997 | 683 | 0.100 |
Why?
|
| Women's Health | 1 | 2015 | 360 | 0.100 |
Why?
|
| Child | 2 | 2020 | 4174 | 0.100 |
Why?
|
| Adolescent Behavior | 1 | 1993 | 185 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 357 | 0.100 |
Why?
|
| Training Support | 1 | 2012 | 19 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 555 | 0.100 |
Why?
|
| Motivation | 3 | 2015 | 273 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5128 | 0.090 |
Why?
|
| Patient Care Team | 2 | 2013 | 326 | 0.090 |
Why?
|
| Educational Status | 1 | 2012 | 264 | 0.090 |
Why?
|
| Genotype | 1 | 2012 | 617 | 0.090 |
Why?
|
| Psychometrics | 3 | 2005 | 362 | 0.090 |
Why?
|
| Affect | 3 | 2017 | 123 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 103 | 0.080 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 153 | 0.080 |
Why?
|
| Pharmacists | 1 | 2009 | 122 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 210 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 149 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6071 | 0.070 |
Why?
|
| Color Perception | 2 | 1997 | 4 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 239 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2006 | 54 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2006 | 47 | 0.070 |
Why?
|
| Naltrexone | 2 | 2018 | 77 | 0.070 |
Why?
|
| New Jersey | 2 | 2004 | 26 | 0.070 |
Why?
|
| Time Factors | 3 | 2015 | 3617 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 481 | 0.060 |
Why?
|
| Self Report | 2 | 2020 | 359 | 0.060 |
Why?
|
| Galvanic Skin Response | 2 | 2015 | 23 | 0.060 |
Why?
|
| Smoking | 2 | 2016 | 826 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 1561 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 441 | 0.060 |
Why?
|
| Pirenzepine | 1 | 2003 | 5 | 0.060 |
Why?
|
| Ambulatory Care | 2 | 2023 | 300 | 0.050 |
Why?
|
| HIV Infections | 1 | 2010 | 913 | 0.050 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 589 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1306 | 0.050 |
Why?
|
| England | 1 | 2022 | 24 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2002 | 116 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 129 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 151 | 0.050 |
Why?
|
| Problem Solving | 1 | 2002 | 30 | 0.050 |
Why?
|
| Reaction Time | 1 | 2002 | 119 | 0.050 |
Why?
|
| Universities | 1 | 2022 | 144 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2005 | 510 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 355 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2002 | 133 | 0.050 |
Why?
|
| Dronabinol | 1 | 2020 | 31 | 0.040 |
Why?
|
| Attention | 1 | 2002 | 146 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 18 | 0.040 |
Why?
|
| Social Welfare | 1 | 2020 | 22 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 412 | 0.040 |
Why?
|
| Nicotine | 1 | 2020 | 113 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 69 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 135 | 0.040 |
Why?
|
| Chlorpromazine | 1 | 1999 | 7 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 66 | 0.040 |
Why?
|
| Clozapine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 1252 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 307 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 153 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 545 | 0.040 |
Why?
|
| Drive | 1 | 1997 | 2 | 0.040 |
Why?
|
| Eye Movement Measurements | 1 | 2017 | 20 | 0.040 |
Why?
|
| Color Perception Tests | 1 | 1997 | 1 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 813 | 0.040 |
Why?
|
| Psychological Tests | 1 | 2017 | 45 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2017 | 62 | 0.040 |
Why?
|
| Psychological Theory | 1 | 1997 | 25 | 0.040 |
Why?
|
| Education, Graduate | 1 | 1997 | 15 | 0.040 |
Why?
|
| Executive Function | 1 | 2017 | 61 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 96 | 0.030 |
Why?
|
| Retina | 1 | 1997 | 115 | 0.030 |
Why?
|
| Eye Movements | 1 | 2017 | 82 | 0.030 |
Why?
|
| Research Personnel | 1 | 1997 | 92 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 219 | 0.030 |
Why?
|
| Teaching | 1 | 1997 | 152 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 489 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2002 | 2374 | 0.030 |
Why?
|
| Skin Temperature | 1 | 2015 | 18 | 0.030 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2010 | 103 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 57 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 150 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 716 | 0.030 |
Why?
|
| Body Temperature | 1 | 2015 | 45 | 0.030 |
Why?
|
| Wrist | 1 | 2015 | 33 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 333 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 416 | 0.030 |
Why?
|
| Medicare | 2 | 2009 | 598 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 806 | 0.030 |
Why?
|
| Primary Prevention | 1 | 1993 | 134 | 0.020 |
Why?
|
| Health Education | 1 | 1993 | 182 | 0.020 |
Why?
|
| Wireless Technology | 1 | 2012 | 18 | 0.020 |
Why?
|
| Vocational Guidance | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mass Screening | 1 | 1996 | 645 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 288 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 265 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 93 | 0.020 |
Why?
|
| Quality of Life | 2 | 2009 | 1137 | 0.020 |
Why?
|
| Drug Packaging | 1 | 2009 | 11 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 176 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1166 | 0.020 |
Why?
|
| Population | 1 | 2007 | 14 | 0.020 |
Why?
|
| Classification | 1 | 2007 | 11 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2005 | 54 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 146 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2005 | 115 | 0.020 |
Why?
|
| Benztropine | 1 | 2003 | 2 | 0.010 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2003 | 5 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 32 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 81 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 203 | 0.010 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1999 | 1 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1999 | 6 | 0.010 |
Why?
|
| Color | 1 | 1997 | 21 | 0.010 |
Why?
|
| Weight Gain | 1 | 1999 | 163 | 0.010 |
Why?
|
| Arousal | 1 | 1996 | 41 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 326 | 0.010 |
Why?
|
| Patient Admission | 1 | 1996 | 184 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1997 | 1189 | 0.010 |
Why?
|
| Incidence | 1 | 1996 | 1237 | 0.010 |
Why?
|